Group 1: Impact of Domestic Substitution Policy - The domestic substitution policy is expected to positively influence company orders, particularly from downstream clients such as government agencies and universities [1] - Historical data indicates that client procurement tends to peak in the third and fourth quarters, prompting the company to actively follow up on project developments [1] Group 2: Shareholder Structure and Risks - The controlling shareholder, Ruiyang Technology, is undergoing a forced liquidation of shares due to a margin call, with an estimated total reduction of no more than 30 million yuan [2] - Current passive share reductions will not lead to changes in the company's control or governance structure [2] Group 3: Long-term Growth Strategies - The company aims to achieve a high market share in existing product categories before expanding into new growth areas such as international markets and acquisitions [2] - Emphasis on addressing customer pain points through innovative applications and enhancing marketing services to improve core competitiveness [2] Group 4: Client Composition and Future Planning - Historically, government institutions have made up a significant portion of the client base, but the company plans to increase the share of enterprise clients as business scales up [2] - The strategy includes providing tailored solutions for large enterprises, enhancing brand reputation through customer satisfaction [2] Group 5: Life Sciences Instrumentation Development - The life sciences instrumentation segment, particularly in life research, is performing well, while progress in medical instruments is slower [3] - Future plans involve leveraging existing technology platforms to penetrate related product markets [3]